Cat. No.: HY-101488

CC-885

Name: CC-885
Brand: MedChemExpress
SKU: HY-101488
Price: 150.00 USD
Availability: InStock
Rating: 5 (20 reviews)

20 Cited Publications

Customer Review

Based on 20 publication(s) in Google Scholar

CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a K_d of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer.

For research use only. We do not sell to patients.

Purity: 99.26%
CAS No.: 1010100-07-8
Formula: C₂₂H₂₁ClN₄O₄
Molecular Weight:440.88

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

CC-885 Chemical Structure

CAS No.: 1010100-07-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (20)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

Cereblon

eRF3a/GSPT1

350 nM (Kd)

All Ligands for E3 Ligase Isoforms :

All Eukaryotic Release Factor (eRF) Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
NB-4	IC50	0.00006 μM	Antiproliferative activity against human NB-4 AML cells assessed as inhibition of cell proliferation incubated for 48-72 h by cell proliferation assay. Antiproliferative activity against human NB-4 AML cells assessed as inhibition of cell proliferation incubated for 48-72 h by cell proliferation assay.	27338790
U-937	IC50	0.0016 μM	Antiproliferative activity against human U-937 AML cells assessed as inhibition of cell proliferation incubated for 48-72 h by cell proliferation assay. Antiproliferative activity against human U-937 AML cells assessed as inhibition of cell proliferation incubated for 48-72 h by cell proliferation assay.	27338790
NB-4	DC₅₀	<1 nM	GSPT1 degradation in human NB4 cells, achieving >90% maximal degradation at 1 nM. GSPT1 degradation in human NB4 cells, achieving >90% maximal degradation at 1 nM.	40570036
NB-4	IC50	0.06 nM	Antiproliferative activity against human NB4 acute myeloid leukemia cells. Antiproliferative activity against human NB4 acute myeloid leukemia cells.	40570036
MOLM-13	IC50	0.7 nM	Antiproliferative activity against human MOLM-13 acute myeloid leukemia cells. Antiproliferative activity against human MOLM-13 acute myeloid leukemia cells.	40570036
HL-60	IC50	0.5 nM	Antiproliferative activity against human HL-60 acute myeloid leukemia cells. Antiproliferative activity against human HL-60 acute myeloid leukemia cells.	40570036
PBMC	IC50	1.1 nM	Toxicity against normal human PBMC cells. Toxicity against normal human PBMC cells.	40570036
THLE-2	IC50	11 nM	Toxicity against normal human THLE-2 cells. Toxicity against normal human THLE-2 cells.	40570036
769-P	IC50	23 nM	Cytotoxicity against VHL-mutant renal cell carcinoma 769-P cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay. Cytotoxicity against VHL-mutant renal cell carcinoma 769-P cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.	42089431
786-0	IC50	0.99 nM	Cytotoxicity against VHL-mutant renal cell carcinoma 786-O cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay. Cytotoxicity against VHL-mutant renal cell carcinoma 786-O cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.	42089431
A498	IC50	11.3 nM	Cytotoxicity against VHL-mutant renal cell carcinoma A498 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay. Cytotoxicity against VHL-mutant renal cell carcinoma A498 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.	42089431
CAKI-1	IC50	837 nM	Cytotoxicity against VHL-wild-type renal cell carcinoma Caki-1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay. Cytotoxicity against VHL-wild-type renal cell carcinoma Caki-1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.	42089431
TK-10	IC50	847000 nM	Cytotoxicity against VHL-wild-type renal cell carcinoma TK10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay. Cytotoxicity against VHL-wild-type renal cell carcinoma TK10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.	42089431

In Vitro

CC-885 induces secondary downregulation of proteins including MYC, PLK1, and CDK4 via transcriptional collapse following GSPT1 degradation, while directly recruiting GSPT2, WIZ, and CHD7 to CRBN, in human MOLT-4 and 293T cells^[1].
CC-885 (1-10 μM; 24 h) promotes the ubiquitination of CDK4 and dose-dependently enhances the interaction between CDK4 and CRBN in 293T cells, with maximum interaction observed at 10 μM for 24 h^[2].
CC-885 (5-20 h) selectively degrades endogenous GSPT1 in Crbn^V/V MEFs within 5 h, with sustained degradation observed up to 20 h, while wild-type Crbn^+/+ MEFs are resistant to cereblon E3 ligase modulator CC-885-induced GSPT1 degradation^[1].
CC-885 induces potent cytotoxicity in Crbn^V/V MEFs, which correlates with GSPT1 degradation, while wild-type and Crbn^I/I MEFs are resistant to CC-885-induced cytotoxicity^[1].
CC-885 (10 μM; 8 h) induces CRBN-dependent ubiquitination of wild-type ETS1, but not the ETS1^Y158A mutant, in 769-P and 293T cells^[8].
CC-885 (1 μM (293T cells); 5 nM (786-O cells); 12 h (786-O cells)) enhances the physical interaction between CRBN and transcriptionally active ETS1 p51/p42 isoforms, but not the p27 isoform, in 293T and 786-O cells^[8].
CC-885 requires the ETS1 135-242aa domain for CRBN binding and degradation of ETS1 in 293T cells^[8].
CC-885 (6.25-50 nM; 24-72 h) inhibits the viability of RPMI8226, MM1S, and U266 multiple myeloma cells in a dose- and time-dependent manner^[2].
CC-885 (0.5-10 μM; 12-24 h) induces post-translational degradation of CDK4 via ubiquitination in MM1S, RPMI8226, and U266 multiple myeloma cells in a CRBN-, CRL-, p97-, and proteasome-dependent manner, with maximum degradation observed at 10 μM for 12 h in MM1S cells^[2].
CC-885 (62.5-1000 nM; 24-72 h) potently reduces cell viability in HCCLM3, HepG2, and Huh7 human hepatocellular carcinoma cell lines in a dose- and time-dependent manner, with HCCLM3 cells exhibiting the greatest sensitivity^[3].
CC-885 (100-400 nM; 12 h initial treatment, followed by 14 days of culture in regular medium) suppresses the clonogenic potential of HCCLM3 human hepatocellular carcinoma cells in a dose-dependent manner^[3].
CC-885 (0.01-20 μM) dose-dependently reduces GOLM1 protein levels in HCCLM3 human hepatocellular carcinoma cells, with significant suppression starting at 0.1 μM and near-complete depletion at 20 μM^[3].
CC-885 (1 μM; 4-20 h) gradually reduces GOLM1 protein levels in HCCLM3 human hepatocellular carcinoma cells over time, with significant suppression by 4 h and near-maximal depletion by 20 h^[3].
CC-885 (1 μM) does not alter GOLM1 mRNA levels in HCCLM3 human hepatocellular carcinoma cells, confirming post-translational regulation of GOLM1^[3].
CC-885 (1 μM; 20 h) reduces GOLM1 protein levels in Huh7 and HepG2 human hepatocellular carcinoma cells after 20 h of incubation, confirming the effect is consistent across multiple HCC cell lines^[3].
CC-885 (1 μM CC-885 + 10 μM MG132) increases the ubiquitination of GOLM1 in HCCLM3 human hepatocellular carcinoma cells, facilitating proteasomal degradation of GOLM1^[3].
CC-885 (0.001-1 μM; 24 h for A549 cells, 1 μM; 1-24 h for HEK293T cells) induces post-transcriptional, dose- and time-dependent degradation of BNIP3L in A549 cells and HEK293T cells stably expressing Flag-tagged BNIP3L, and reduces the half-life of BNIP3L protein^[4].
CC-885 (5-200 nM; 16 h) dose-dependently enhances GSPT1 ubiquitination in U87 glioblastoma cells, with maximum activity at 100 nM^[5].
CC-885 (0-10 μM; 72 h) potently inhibits viability of VHL-mutant ccRCC cell lines (769-P, 786-O, A498) with IC₅₀ values ranging from 0.99 nM to 23 nM, while showing minimal activity against VHL-wild-type ccRCC cell lines (Caki-1, TK10, ACHN)^[8].
CC-885 (100 nM (Caki-1 cells); 1 nM (786-O cells); 14 days) suppresses colony formation in VHL-deficient 786-O ccRCC cells and VHL-knockdown Caki-1 ccRCC cells, with VHL status modulating the magnitude of the effect^[8].
CC-885(1 μM; 8 h) downregulates ETS1 mRNA expression in 786-O ccRCC cells^[8].
CC-885 (5-200 nM, 10 nM, 100 nM, 1 μM; 8 h, 12 h, 24 h) selectively degrades transcriptionally active ETS1 p51 and p42 isoforms in VHL-deficient ccRCC cells and 293T cells in a dose-dependent manner, while sparing the dominant-negative p27 isoform^[8].
CC-885 (500 nM; 24 h) reduces viability of A549 NSCLC cells expressing wild-type or mutant PLK1, and (50 nM-1 μM; 24 h) synergistically enhances volasertib-induced viability reduction when used with 50 nM volasertib^[9].
CC-885 (1-50 nM; 1 week) synergistically enhances Volasertib (HY-12137)-induced reduction of clonogenic survival in A549 NSCLC cells^[9].
CC-885 (10-50 nM; 48 h) synergistically enhances Volasertib-induced cell death in A549 NSCLC cells^[9].
CC-885 (10 μM; 12 h) or (2 μM; 24 h) induces CRBN- and proteasome-dependent degradation of PLK1 in A549 and NCI-H1299 NSCLC cells, and this effect requires the C-terminal 19 amino acids of PLK1^[9].
CC-885 (1 μM; 24 h) inhibits activation of PLK1 substrates TCTP and Myt1 in A549 NSCLC cells in a CRBN-dependent manner, and (50 nM; 24 h) synergizes with Volasertib to enhance this inhibition^[9].
CC-885 (0.1-10 μM; 2 h) promotes CRBN-PLK1 binding in A549 NSCLC cells, and (1 μM; 12 h) induces CRBN- and p97-dependent ubiquitination and degradation of PLK1^[9].
CC-885 (100 nM; 24 h) induces G1 phase cell cycle arrest in RPMI8226 and MM1S multiple myeloma cells at a concentration of 100 nM for 24 h^[2].
CC-885 (100-500 nM; 24 h) inhibits E2F luciferase activity in 293T cells in a dose-dependent manner at concentrations of 100 and 500 nM for 24 h, and in MM1S multiple myeloma cells at 1 μM for 24 h, it reduces expression of E2F downstream target genes and decreases RB phosphorylation at Ser780^[2].
CC-885 (250-1000 nM) inhibits DNA synthesis in HCCLM3 human hepatocellular carcinoma cells^[3].
CC-885 (50-100 nM; 72 h) induces dose-dependent cell death in RPMI8226 and MM1S multiple myeloma cells at concentrations of 50 and 100 nM for 72 h^[2].
CC-885 (0.1-10 μM) induces apoptosis in HCCLM3 human hepatocellular carcinoma cells, as shown by increased cleaved caspase-3 and BAX levels, and decreased Bcl-2 and full-length caspase-3 levels^[3].
CC-885 (2.5-10 μM; 48 h) increases early and late apoptosis rates in HCCLM3 human hepatocellular carcinoma cells after 48 h of incubation^[3].
CC-885 (250-1000 nM; 24-48 h post-wounding) inhibits the migration of HCCLM3 human hepatocellular carcinoma cells in a dose-dependent manner, as measured by reduced wound closure at 24 h and 48 h^[3].
CC-885 (250-1000 nM; 24-48 h) reduces the invasive potential of HCCLM3 human hepatocellular carcinoma cells in a dose-dependent manner^[3].
CC-885 (1 μM; 24 h) modulates gene expression in HCCLM3 human hepatocellular carcinoma cells after 24 h of incubation, activating key pathways including apoptosis, IL6/JAK/STAT3 signaling, inflammatory response, and TNFA signaling via NFKB^[3].
CC-885 (200 nM; 12 h) induces CRBN-dependent downregulation of 36 proteins (including BNIP3L) in A549 cells and enriches the negative macromitophagy pathway, with BNIP3L degradation not occurring in CRBN^−/− HEK293T cells^[4].
CC-885 (1 μM; 24 h pre-incubation followed by 4 h CCCP treatment) abrogates CCCPHY-100941)-induced mitophagy in HCT116 cells by reducing colocalization of autophagosomes and mitochondria^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

human multiple myeloma cell lines RPMI8226, MM1S, U266
Concentration:

6.25-50 nM (monotherapy); 1 μM (combination with CDK4 knockdown or palbociclib)
Incubation Time:

24-72 h (monotherapy); 24 h (combination with CDK4 knockdown or palbociclib)
Result:

Induced dose- and time-dependent growth inhibition in RPMI8226, MM1S, and U266 cells.
Reduced cell viability to a greater extent in MM1S cells pre-silenced for CDK4 than in control shRNA cells when treated at 1 μM for 24 h.
Produced greater growth inhibition in MM1S cells when co-used with 1 μM palbociclib for 24 h than either agent alone.

Cell Cycle Analysis^[2]

Cell Line:

human multiple myeloma cell lines RPMI8226, MM1S
Concentration:

100 nM
Incubation Time:

24 h
Result:

Induced cell cycle arrest in the G1 phase compared with DMSO treatment in both RPMI8226 and MM1S cells.

Apoptosis Analysis^[2]

Cell Line:

human multiple myeloma cell lines RPMI8226, MM1S
Concentration:

50-100 nM
Incubation Time:

72 h
Result:

Induced dose-dependent cell death in both RPMI8226 and MM1S cells.

Western Blot Analysis^[2]

Cell Line:

human multiple myeloma cell lines MM1S, RPMI8226, U266, CRISPR-edited CRBN-deficient MM1S cells; 293T cells transfected with Flag-CDK4
Concentration:

0.5-10 μM (MM1S dose-response; 12 h); 1 μM (MM1S time-response; 2-24 h); 1 μM (RPMI8226, U266, MM1S; 24 h); 10 μM (293T Flag-CDK4; 24 h); 100 nM (MM1S cycloheximide chase pre-treatment); 1 μM (MM1S with proteasome inhibitor/CRL inhibitor/p97 inhibitor; 24 h); 1-10 μM (293T Flag-CDK4 with CRL inhibitor; 24 h)
Incubation Time:

12 h (MM1S dose-response); 2-24 h (MM1S time-response); 24 h (RPMI8226, U266, MM1S, 293T Flag-CDK4, MM1S with proteasome inhibitor/CRL inhibitor/p97 inhibitor, 293T Flag-CDK4 with CRL inhibitor); 2 h (MM1S cycloheximide chase pre-treatment, followed by 2-10 h cycloheximide treatment)
Result:

Reduced CDK4 protein expression in MM1S cells in a dose- and time-dependent manner.
Reduced endogenous CDK4 protein in RPMI8226 and U266 cells without altering CDK4 mRNA levels.
Reduced exogenous Flag-CDK4 protein in 293T cells.
Had its induced CDK4 degradation reversed by proteasome inhibitor, CRL inhibitor, and p97 inhibitor in MM1S cells.
Shortened the half-life of CDK4 protein in MM1S cells via cycloheximide chase assays.
Failed to induce CDK4 degradation in CRBN-deficient MM1S cells, while re-expression of CRBN restored this effect.

Western Blot Analysis^[2]

Cell Line:

293T cells transfected with Flag-CDK4
Concentration:

10 μM (ubiquitination assay); 1-10 μM (CRBN interaction assay)
Incubation Time:

24 h (ubiquitination assay, with additional 6 h proteasome inhibitor treatment); 24 h (CRBN interaction assay with NEDD8-activating enzyme inhibitor)
Result:

Induced ubiquitination of Flag-CDK4 in 293T cells.
Promoted the interaction between Flag-CDK4 and CRBN in a dose-dependent manner in 293T cells.

Cell Viability Assay^[3]

Cell Line:

HCCLM3, HepG2, Huh7 human hepatocellular carcinoma cell lines
Concentration:

62.5-1000 nM
Incubation Time:

24 h, 48 h, 72 h
Result:

Caused a significant, dose-dependent reduction in cell viability across all three HCC cell lines at all three incubation time points.
Showed the highest sensitivity in HCCLM3 cells compared to HepG2 and Huh7 cells.

Cell Proliferation Assay^[3]

Cell Line:

HCCLM3 human hepatocellular carcinoma cell line
Concentration:

100-400 nM
Incubation Time:

12 h initial treatment, followed by 14 days of culture in regular medium
Result:

Caused a pronounced, concentration-dependent decline in the number of colonies formed by HCCLM3 cells, indicating reduced long-term cell survival and proliferation.

Cell Migration Assay^[3]

Cell Line:

HCCLM3 human hepatocellular carcinoma cell line
Concentration:

250-1000 nM
Incubation Time:

24 h, 48 h post-wounding
Result:

Significantly impeded the migratory capacity of HCCLM3 cells, with greater inhibition observed at higher concentrations at both 24 h and 48 h post-treatment.

Cell Invasion Assay^[3]

Cell Line:

HCCLM3 human hepatocellular carcinoma cell line
Concentration:

250-1000 nM
Incubation Time:

24-48 h
Result:

Resulted in a substantial reduction in the number of invaded HCCLM3 cells, with higher concentrations leading to greater inhibitory effects.

Western Blot Analysis^[3]

Cell Line:

HCCLM3 human hepatocellular carcinoma cell line
Concentration:

1 μM
Incubation Time:

4-20 h
Result:

Caused a gradual and sustained decrease in GOLM1 protein levels, with significant reductions observed after 4 h and minimal levels reached by 20 h.

Western Blot Analysis^[3]

Cell Line:

Huh7, HepG2 human hepatocellular carcinoma cell lines
Concentration:

1 μM
Incubation Time:

20 h
Result:

Significantly reduced GOLM1 protein levels in both Huh7 and HepG2 cells, indicating the effect is not cell line-specific.

Apoptosis Analysis^[3]

Cell Line:

HCCLM3 human hepatocellular carcinoma cell line
Concentration:

2.5-10 μM
Incubation Time:

48 h
Result:

Significantly elevated both early and late apoptosis rates in HCCLM3 cells.

Western Blot Analysis^[4]

Cell Line:

human non-small cell lung cancer A549 cells, human embryonic kidney HEK293T cells stably expressing Flag-tagged BNIP3L
Concentration:

0.001-1 μM (A549 cells); 1 μM (HEK293T cells); 1 μM (HEK293T cells, pre-incubation)
Incubation Time:

24 h (A549 cells); 1-24 h (HEK293T cells); 2 h pre-incubation, followed by 0.5-8 h CHX treatment (HEK293T cells)
Result:

Decreased endogenous BNIP3L protein levels in A549 cells in a dose-dependent manner.
Decreased Flag-BNIP3L protein levels in HEK293T cells in a time-dependent manner, with reductions detectable at 6 h.
Significantly decreased the half-life of Flag-BNIP3L protein compared to CHX treatment alone.
Left BNIP3L mRNA levels in A549 cells unaltered after treatment.

Cell Viability Assay^[8]

Cell Line:

VHL-wild-type renal cell carcinoma (ccRCC) cell lines (Caki-1, TK10, ACHN); VHL-mutant ccRCC cell lines (786-O, 769-P, A498)
Concentration:

0-10 μM
Incubation Time:

72 h
Result:

Exhibited selective cytotoxicity, with significantly lower IC₅₀ values in VHL-mutant cell lines: 769-P (23 nM), 786-O (0.99 nM), A498 (11.3 nM).
Showed much higher IC₅₀ values in VHL-wild-type cell lines: Caki-1 (837 nM), TK10 (847000 nM), and no IC₅₀ was detected in ACHN cells.
Reduced sensitivity in VHL-reconstituted 786-O or 769-P cells, which was rescued by CRBN overexpression.
Enhanced sensitivity in VHL-knockdown Caki-1 or TK10 cells, an effect reversed by CRBN knockout.

Real Time qPCR^[8]

Cell Line:

786-O ccRCC cells
Concentration:

1 μM
Incubation Time:

8 h
Result:

Reduced relative ETS1 mRNA expression.
Showed no significant effect on HBB mRNA expression.
Increased GNPTAB mRNA expression.
Increased ISYNA1 mRNA expression.

Western Blot Analysis^[8]

Cell Line:

786-O, 769-P, 293T cells
Concentration:

100 nM (786-O cells, 24 h); 5-200 nM (786-O, 769-P, 293T cells, 24 h); 10 nM (786-O cells, 12 h); 1 μM (786-O cells, 8 h)
Incubation Time:

8 h (786-O cells, 1 μM); 12 h (786-O cells, 10 nM); 24 h (786-O, 769-P, 293T cells, 5-200 nM, 100 nM)
Result:

Dose-dependently reduced endogenous ETS1 p51 and p42 isoform protein levels in 786-O and 769-P cells, while leaving the p27 isoform unaffected; proteasome inhibitor MG132 co-treatment rescued ETS1 degradation.
Selectively degraded FLAG-tagged ETS1 p51 and p42 isoforms in 293T cells, but not p27.
Reduced ETS1 protein levels in 786-O cells, with no significant effect on GSPT1 levels.

Cell Viability Assay^[9]

Cell Line:

A549 non-small-cell lung cancer (NSCLC) cells
Concentration:

500 nM (alone); 50 nM (in combination with 50 nM volasertib); 1 μM (in combination with 50 nM volasertib)
Incubation Time:

24 h
Result:

Reduced cell viability in A549 cells stably expressing wild-type PLK1, PLK1-F183L, and PLK1-L59W when used alone at 500 nM for 24 h.
Synergistically enhanced volasertib-induced cell viability reduction in A549 cells when combined with 50 nM volasertib at 50 nM for 24 h.
Reduced A549 cell viability compared to volasertib alone when combined with 50 nM volasertib at 1 μM for 24 h.

Apoptosis Analysis^[9]

Cell Line:

A549 NSCLC cells
Concentration:

10 nM (in combination with 50 nM volasertib); 50 nM (in combination with 50 nM volasertib)
Incubation Time:

48 h
Result:

Increased A549 cell death compared to volasertib alone when combined with 50 nM volasertib at 10 nM for 48 h.
Amplified the cell death effect further when combined with 50 nM volasertib at 50 nM for 48 h.

Western Blot Analysis^[9]

Cell Line:

A549 NSCLC cells, NCI-H1299 NSCLC cells, 293T cells
Concentration:

1 μM; 2 μM; 100 nM; 0, 0.5, 1, 5, 10 μM
Incubation Time:

12 h, 24 h (1 μM); 0, 4, 8, 10, 12, 24 h (2 μM); 2 h pretreatment, then 0, 2, 4, 8, 10 h co-treatment with cycloheximide (100 nM); 12 h (0, 0.5, 1, 5, 10 μM)
Result:

Induced dose-dependent reduction of PLK1 protein in A549 cells at 0, 0.5, 1, 5, 10 μM for 12 h.
Induced time-dependent reduction of PLK1 protein in A549 cells at 2 μM over 0-24 h.
Reduced PLK1 protein in A549 cells stably expressing wild-type PLK1, PLK1-F183L, and PLK1-L59W at 1 μM for 12 h, with degradation blocked by pretreatment with 10 μM proteasome inhibitor MG132 or 1 μM NEDD8-activating enzyme inhibitor MLN4924.
Reduced the half-life of PLK1 in cycloheximide chase assays at 100 nM.
Reduced PLK1 and GSPT1 protein in A549 CRBN+/+ cells, but not in CRBN−/− cells, at 1 μM for 24 h; effect restored in CRBN−/− cells transfected with wild-type CRBN, but not IMiD-resistant CRBN-YW/AA.
Reduced PLK1 and GSPT1 protein in NCI-H1299 cells with control shRNA, but not in cells with CRBN-targeting shRNAs, at 1 μM for 24 h.
Reduced full-length PLK1, PLK1-1-305, and PLK1-1-480 protein, but not PLK1-1-584 (lacking the C-terminal 19 amino acids), in 293T cells at 1 μM for 12 h.

Western Blot Analysis^[9]

Cell Line:

A549 NSCLC cells
Concentration:

1 μM; 50 nM (in combination with 50 nM volasertib)
Incubation Time:

24 h
Result:

Reduced phosphorylation of TCTP (Ser46) and Myt1 (Ser83) in A549 CRBN+/+ cells, but not in CRBN−/− cells or cells pretreated with MG132 or MLN4924, at 1 μM for 24 h.
Caused greater reduction of phosphorylated TCTP and Myt1 than either agent alone when combined with 50 nM volasertib at 50 nM for 24 h.

In Vivo

CC-885 (5 mg/kg; i.p.; single dose) induces lethal multi-organ toxicity driven by selective GSPT1 degradation in humanized Crbn^V380E C57BL/6 mice^[1].
CC-885 (5 mg/kg; i.p.; single dose) does not induce toxicity in double mutant humanized Crbn^V380E/Gspt1^G574N C57BL/6 mice due to abrogated GSPT1 degradation^[1].
CC-885 (30 mg/kg; i.p.; daily; 4 weeks) inhibits tumor growth and reduces tumor weight in a BALB/cA nude mouse multiple myeloma xenograft model^[2].
CC-885 (5-20 mg/kg; i.p.; twice daily; 21 days) dose-dependently suppresses orthotopic hepatocellular carcinoma tumor growth in BALB/c mice, with near-complete inhibition at the 20 mg/kg dose, and reduces GOLM1 protein levels in tumor tissues^[3].
CC-885 (25 mg/kg; i.p.; once every 3 days) reduces tumor weight in 786-O VHL-deficient ccRCC xenograft models, with enhanced efficacy in CRBN-overexpressing tumors^[8].
CC-885 (20 mg/kg; i.p.; three times per week; 4 weeks) inhibits NSCLC xenograft tumor growth, and produces a marked reduction in tumor volume and weight when combined with Volasertib (HY-12137)^[9].
CC-885 (50-100 mg/kg; i.p.; once every alternate day on days 16, 18, 20, 22; total 4 doses) significantly reduces glioblastoma tumor growth, lowers tumor cell proliferation markers, increases tumor cell apoptosis, and prolongs survival in nude mice with intracranial U87 glioblastoma xenografts^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (humanized CrbnV380E, gender/age/weight not specified, CRISPR-Cas9 knock-in model)^[1]
Dosage:

5 mg/kg
Administration:

i.p.; single dose
Result:

Induced acute morbidity characterized by decline in body temperature, profound lethargy, and subsequent death.
Caused selective depletion of endogenous GSPT1 in tissues.
Triggered intestinal distension with turbid yellow exudate, complete paralytic ileus, crypt abscesses, villus disruption, and widespread crypt cell apoptosis.
Induced systemic inflammation with elevated neutrophils and monocytes, lymphopenia via severe CD19+ B cell loss, splenic white pulp atrophy and apoptosis.
Caused hepatic injury with icteric liver parenchyma, altered plasma transaminase (ALT, AST), bilirubin (DBIL, TBIL), and albumin (ALB) levels, and hepatic congestion/stasis.

Animal Model:

C57BL/6 (double mutant: humanized CrbnV380E + degradation-resistant Gspt1G574N, gender/age/weight not specified, knock-in model)^[1]
Dosage:

5 mg/kg
Administration:

i.p.; single dose
Result:

Failed to induce GSPT1 degradation in spleen or liver.
Fully protected mice against lethality, lethargy, and physical deterioration.
Preserved normal intestinal morphology with no paralytic ileus or fluid accumulation.
Maintained normal neutrophil, lymphocyte, and platelet counts, and protected bone marrow B-cell populations.
Preserved baseline serum levels of ALT, AST, and bilirubin, indicating intact hepatic function.

Animal Model:

BALB/cA (male, subcutaneous multiple myeloma xenograft via injection of 1×10⁷ RPMI8226 cells)^[2]
Dosage:

30 mg/kg
Administration:

i.p.; daily; 4 weeks
Result:

Inhibited tumor growth.
Reduced final tumor volumes.
Reduced tumor weights.

Animal Model:

BALB/c (orthotopic hepatocellular carcinoma model via injection of 1×10⁶ EGFP-expressing HCCLM3 cells into the liver)^[3]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.p.; twice daily; 21 days
Result:

Reduced bioluminescence intensity to approximately 70% of control levels at 5 mg/kg.
Reduced bioluminescence intensity to 20% of control levels at 10 mg/kg.
Reduced bioluminescence intensity to nearly undetectable levels at 20 mg/kg.
Reduced GOLM1 protein levels in mouse liver tumor tissues.

Animal Model:

BALB/c-nu/nu nude mice (8-week-old male; intracranial transplantation of 1×10⁶ U87 glioblastoma cells expressing iRFP720)^[5]
Dosage:

50 mg/kg; 100 mg/kg
Administration:

i.p.; once every alternate day on days 16, 18, 20, 22; total 4 doses
Result:

Reduced tumor-associated iRFP720 fluorescence intensity compared to controls.
Significantly prolonged survival periods compared to controls.
Reduced GSPT1 protein expression in tumor tissue compared to controls.
Induced tumor cell swelling, multinucleation, and increased polymorphism.
Significantly reduced Ki-67 proliferation index in tumor tissue compared to controls.
Significantly reduced phosphorylated ERK1/2 in tumor tissue compared to controls.
Significantly increased relative cleaved caspase-3 positive area in tumor tissue compared to controls.

Animal Model:

Immunocompromised mice^[8]
Dosage:

25 mg/kg
Administration:

i.p.; once every 3 days
Result:

Reduced final tumor weights in empty vector group, VHL overexpression group, CRBN overexpression group, and VHL+CRBN overexpression group, with the greatest reduction observed in the CRBN overexpression group.

Animal Model:

BALB/cA nude mice^[9]
Dosage:

20 mg/kg
Administration:

i.p.; three times per week; 4 weeks
Result:

Inhibited NSCLC xenograft tumor growth.
Produced a marked reduction in tumor volume and weight when combined with Volasertib.

Chemical Information

CAS No. 1010100-07-8
Appearance Solid
Molecular Weight 440.88
Formula C₂₂H₂₁ClN₄O₄
Color White to off-white
SMILES

O=C(NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1)NC4=CC=C(C)C(Cl)=C4
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (20)

All WBCell Proliferation/Viability AssayRT-PCR

Sort by:

Journal Impact Factor

Cell

Mechanisms of readthrough mitigation reveal principles of GCN1-mediated translational quality control. [Abstract]

2023 Jul 20;186(15):3227-3244.e20. PMID: 37339632

CC-885 purchased from MedChemExpress. Usage Cited in: Cell. 2023 Jul 20;186(15):3227-3244.e20. [Abstract]

Immunoblot analysis of eRF3 upon treatment of HEK293T cells with CC-885 (10 nM) and G418 (20 μg/mL) for 4 h to induce readthrough (n = 3).
Cancer Discov

TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers. [Abstract]

2026 Apr 19. PMID: 42001523
Nat Commun

A degron-mimicking molecular glue drives CRBN homo-dimerization and degradation. [Abstract]

2025 Nov 19;16(1):10157. PMID: 41258141
Nat Commun

Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery. [Abstract]

2023 Dec 19;14(1):8437. PMID: 38114468

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Dec 19;14(1):8437. [Abstract]

Degradation of neo-substrates by CC-885 (0.00001-10000 nM) in MM.1 S cells after 16 h treatment. Graph bars represent mean values ± SD. n = 3 independent biological replicates. Immunoblot experiment was performed to check protein level. Quantitative protein analysis was performed by software Image J. Source data are provided as a Source Data file.

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Dec 19;14(1):8437. [Abstract]

Western blot using lysates from Ba/F3 cells overexpressing Crbn constructs with combinations of humanization mutations E152D, V380E, and I391V as indicated. Protein lysates were harvested following 6 hours of treatment with 1 μM CC-885.
Nat Commun

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. [Abstract]

2022 Sep 10;13(1):5324. PMID: 36088459

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]

RT-qPCR data showing expression of COL1A1 and COL3A1 upon treatment of LX2 cells (left panel) or EMS404 cells (right panel) with increasing concentrations of CC-885 (0.001-1 μM) or vehicle for 24h (n=3 biologically independent experiments). Log2 FC between drug and vehicle-treated cells are shown. The bar graph shows means ±SD.
Mol Cell

Mechanism of RACK1-dependent ZAKα activation at stalled and collided ribosomes. [Abstract]

2026 Jun 18;86(12):2341-2357.e10. PMID: 42214329
Nat Chem Biol

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates. [Abstract]

2024 Sep;20(9):1227-1236. PMID: 38514884

CC-885 purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2024 Sep;20(9):1227-1236. [Abstract]

GSPT1, VCL and ETF1 proteins in 293T cells treated with CC-885 (1 μM; 0.5-24 h) over the indicated time course were analyzed by immunoblotting.
J Clin Invest

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. [Abstract]

2022 Aug 15;132(16):e153514. PMID: 35763353

CC-885 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2022 Aug 15;132(16):e153514. [Abstract]

Cell viability in MOLM13 cells expressing GSPT1-ETF1Δ (drug sensitive and drug resistant; G575N). For all CellTiter-Glo luminescent assays, cell viability was assessed 72 hours after treatment with CC-885 (0.001-1 μM, graphs represent combined data from 3 biological replicates performed in technical triplicate; symbols represent mean ± SEM).
Acta Pharmacol Sin

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. [Abstract]

2020 Sep;41(9):1246-1254. PMID: 32210356
Cell Chem Biol

A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. [Abstract]

2020 Jul 16;27(7):866-876.e8. PMID: 32413286
Leukemia

Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. [Abstract]

2025 Sep;39(9):2163-2173. PMID: 40670672
Mol Ther Oncolytics

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. [Abstract]

2020 Jun 23;18:215-225. PMID: 32728610
Bioorg Chem

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. [Abstract]

2022 Feb:119:105505. PMID: 34838332
Cell Signal

Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression. [Abstract]

2025 Jun:130:111665. PMID: 39986359
J Proteome Res

SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics. [Abstract]

2022 Aug 5;21(8):1842-1856. PMID: 35848491
Dis Model Mech

Recovery of α-L-Fucosidase in Fucosidosis nonsense variants by readthrough stimulation and release factor degradation. [Abstract]

2025 Nov 7:dmm.052495. PMID: 41200823
Biochem Biophys Res Commun

Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. [Abstract]

2021 Apr 16:549:150-156. PMID: 33676183
bioRxiv

2026 Feb 16.
bioRxiv

Slice-PASEF: Maximising Ion Utilisation in LC-MS Proteomics. [Abstract]

2025 Sep 2:2022.10.31.514544. PMID: 40950106
bioRxiv

2024 Jan 28.

Solvent & Solubility

In Vitro:

DMSO : 66.67 mg/mL (151.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2682 mL

11.3410 mL

22.6819 mL

5 mM

0.4536 mL

2.2682 mL

4.5364 mL

10 mM

0.2268 mL

1.1341 mL

2.2682 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.25 mg/mL (5.10 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.25 mg/mL (5.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (325 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yi-Sheng Pu, et al. On-target toxicity of GSPT1 molecular glue degraders in mice. bioRxiv, February 16, 2026.

[2]. Zhao M, et al. Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. Biochemical and biophysical research communications. 2021 Apr 16;549:150-156. [Content Brief]

[3]. He J, et al. Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression. Cellular signalling. 2025 Jun;130:111665. [Content Brief]

[4]. Hao BB, et al. The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. Acta pharmacologica Sinica. 2020 Sep;41(9):1246-1254. [Content Brief]

[5]. Sasayama T, et al. Potential of GSPT1 as a novel target for glioblastoma therapy. Cell death & disease. 2024 Aug 08;15(8):572.

[6]. Matyskiela ME, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016 Jul 14;535(7611):252-7. [Content Brief]

[7]. Cheng B, et al. Research Progress in Targeting GSPT1: Molecular Glues, Bifunctional Degraders, and Antibody-Enabled Molecular Glues for Cancer Therapy. Journal of medicinal chemistry. 2025 Jul 10;68(13):13169-13185.

[8]. Yang T, et al. Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2026 Jul;13(42):e20237.

[9]. Li L, et al. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. Molecular therapy oncolytics. 2020 Sep 25;18:215-225. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2682 mL	11.3410 mL	22.6819 mL	56.7048 mL
	5 mM	0.4536 mL	2.2682 mL	4.5364 mL	11.3410 mL
	10 mM	0.2268 mL	1.1341 mL	2.2682 mL	5.6705 mL
	15 mM	0.1512 mL	0.7561 mL	1.5121 mL	3.7803 mL
	20 mM	0.1134 mL	0.5670 mL	1.1341 mL	2.8352 mL
	25 mM	0.0907 mL	0.4536 mL	0.9073 mL	2.2682 mL
	30 mM	0.0756 mL	0.3780 mL	0.7561 mL	1.8902 mL
	40 mM	0.0567 mL	0.2835 mL	0.5670 mL	1.4176 mL
	50 mM	0.0454 mL	0.2268 mL	0.4536 mL	1.1341 mL
	60 mM	0.0378 mL	0.1890 mL	0.3780 mL	0.9451 mL
	80 mM	0.0284 mL	0.1418 mL	0.2835 mL	0.7088 mL
	100 mM	0.0227 mL	0.1134 mL	0.2268 mL	0.5670 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CC-885

Publications Citing Use of MedChemExpress (MCE) CC-885

All Ligands for E3 Ligase Isoforms

All Eukaryotic Release Factor (eRF) Isoforms